Results 331 to 340 of about 1,859,821 (399)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Mental health burden in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis: Depression and anxiety. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Javorac J, Živanović D, Miladinović M, Mikić A, Dukanac V, Ilić M, Milenković A, Peričević Medić S, Popović T, Kašiković Lečić S.   +9 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations. [PDF]

Biomedicines
Raineri G, Samarelli AV, Tonelli R, Masciale V, Aramini B, Petrachi T, Bruzzi G, Gozzi F, Trasforini E, Esposito A, Azzali F, Dominici M, Eccher A, Cerri S, Clini E.   +14 more
europepmc   +1 more source

Effects of proportional assist ventilation on exercise capacity in idiopathic pulmonary fibrosis patients

, 2007
Eliana Vieira Moderno
openalex   +1 more source

Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications. [PDF]

Front Immunol
Liang X, Li Y, Tang Z, Luo Y, Liu Y.
europepmc   +1 more source

Mechanistic Evaluation of Roxadustat for Pulmonary Fibrosis: Integrating Network Pharmacology, Transcriptomics, and Experimental Validation. [PDF]

Pharmaceuticals (Basel)
Zhang C, Huang X, Ye H, Tang H, Huang M, Jia S, Shao J, Wu J, Yao X.   +8 more
europepmc   +1 more source

Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Chandani DK, Khan MS, Mahmoud A.   +4 more
europepmc   +1 more source

The Role of Particle Inhalation in Idiopathic Pulmonary Fibrosis. [PDF]

Int J Mol Sci
Ghio AJ, Sangani RG, Todd NW.
europepmc   +1 more source

Assessing the Impact of Colchicine on Pulmonary Fibrosis Using Imaging in Patients With Moderate-to-Severe COVID-19 Pneumonia. [PDF]

Can Respir J
Ayhan Albayrak G, Bardakci MI, Temel U.
europepmc   +1 more source